Sumario: | Posttraumatic stress disorder (PTSD) is the third most common psychiatric diagnosis among Veterans seen in the Veterans Health Administration (VHA). PTSD can be debilitating, leading to a decline in quality of life (QoL) and causing significant medical, mental health, interpersonal, and social impairment. First-line treatments for PTSD include psychotherapy, pharmacotherapy, or their combination; however, several challenges have been identified in their effectiveness and reach. Stellate ganglion block (SGB), also called cervical sympathetic block, has been promoted as an adjuvant in individuals with PTSD who have not fully responded to conventional therapies. Our objectives were (1) to determine to what extent SGB provides clinically relevant benefits for patients with PTSD, (2) to determine SGB's potential harms, and (3) to identify veterans who are most likely to benefit from SGB. Our objectives were (1) to determine to what extent SGB provides clinically relevant benefits for patients with PTSD, (2) to determine SGB's potential harms, and (3) to identify Veterans who are most likely to benefit from SGB.
|